Michael Barbella, Managing Editor04.30.24
New clinical data validates Viz.ai's artificial intelligence-based Viz PE Solution in managing pulmonary embolisms (PE) and improving outcomes.
The real-world study, “Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software,” evaluated Viz PE Solution's clinical impact on time to assessment, time to anticoagulation, and patient outcomes. The study found that implementing the AI-powered solution, along with PERT activation, significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.
“Our findings highlight the efficacy and practical application of AI in a clinical setting,” said Jacob Shapiro, M.D., vascular surgery resident at TriHealth in Cincinnati, Ohio. “We are proud to partner with Viz.ai and utilize their PE solutions to continue advancing the management of this vulnerable patient population.”
“The results of this study mark a significant milestone in our ongoing journey to improve patient outcomes with AI,” added Prem Batchu-Green, senior director of clinical strategy at Viz.ai. “By showcasing the real-world impact of the Viz PE Solution on key metrics such as mortality, we are not only validating the effectiveness of our technology but also reaffirming our commitment to driving meaningful change in healthcare for the benefit of patients.”
Viz.ai uses AI algorithms and machine learning to increase the speed of diagnosis and care across U.S. and European hospitals and health systems. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies.
The real-world study, “Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software,” evaluated Viz PE Solution's clinical impact on time to assessment, time to anticoagulation, and patient outcomes. The study found that implementing the AI-powered solution, along with PERT activation, significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.
“Our findings highlight the efficacy and practical application of AI in a clinical setting,” said Jacob Shapiro, M.D., vascular surgery resident at TriHealth in Cincinnati, Ohio. “We are proud to partner with Viz.ai and utilize their PE solutions to continue advancing the management of this vulnerable patient population.”
“The results of this study mark a significant milestone in our ongoing journey to improve patient outcomes with AI,” added Prem Batchu-Green, senior director of clinical strategy at Viz.ai. “By showcasing the real-world impact of the Viz PE Solution on key metrics such as mortality, we are not only validating the effectiveness of our technology but also reaffirming our commitment to driving meaningful change in healthcare for the benefit of patients.”
Viz.ai uses AI algorithms and machine learning to increase the speed of diagnosis and care across U.S. and European hospitals and health systems. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies.